Researchers mimic mussels for delivery 'glue'; HGH nasal spray passes second clinical trial;

> Researchers at Northwestern University are using a material based on the glue that holds mussels to rocks underwater to help during surgical repair and polymer-based drug delivery. Release

> Critical Pharmaceuticals completed a second clinical study of its CP024 human growth hormone nasal spray, an alternative to injections for children and adults with growth disorders. Release

> New Jersey-based mPhase Technologies filed a patent application for a novel drug delivery system based on its Smart Surface technology, which enables the precise control of a fluid on a nano-structured surface. Release

> Mylan ($MYL) entered into an agreement with Biocon for the global development and commercialization of Biocon's insulin analog products with a potential market of $11.5 billion. Biocon is also in the market with Bristol-Myers Squibb ($BMY) and the company's pursuit of oral insulin approval. Story

> Gamida Cell saw successful results in its Phase I/II study of NiCord, stem cells derived from the umbilical cord that are designed to treat patients with high-risk blood disorders. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.